[go: up one dir, main page]

DK0669832T3 - Fremgangsmåde til behandling eller forebyggelse af fedme - Google Patents

Fremgangsmåde til behandling eller forebyggelse af fedme

Info

Publication number
DK0669832T3
DK0669832T3 DK93925058.5T DK93925058T DK0669832T3 DK 0669832 T3 DK0669832 T3 DK 0669832T3 DK 93925058 T DK93925058 T DK 93925058T DK 0669832 T3 DK0669832 T3 DK 0669832T3
Authority
DK
Denmark
Prior art keywords
preventing obesity
treating
growth hormone
effective amount
mammals
Prior art date
Application number
DK93925058.5T
Other languages
Danish (da)
English (en)
Inventor
Ross G Clark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0669832T3 publication Critical patent/DK0669832T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK93925058.5T 1992-10-29 1993-10-26 Fremgangsmåde til behandling eller forebyggelse af fedme DK0669832T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96862392A 1992-10-29 1992-10-29

Publications (1)

Publication Number Publication Date
DK0669832T3 true DK0669832T3 (da) 1997-03-17

Family

ID=25514516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93925058.5T DK0669832T3 (da) 1992-10-29 1993-10-26 Fremgangsmåde til behandling eller forebyggelse af fedme

Country Status (13)

Country Link
EP (1) EP0669832B1 (fr)
JP (1) JPH08502969A (fr)
AT (1) ATE143267T1 (fr)
AU (1) AU675996B2 (fr)
CA (1) CA2145501C (fr)
DE (1) DE69305091T2 (fr)
DK (1) DK0669832T3 (fr)
ES (1) ES2095086T3 (fr)
GR (1) GR3022074T3 (fr)
LV (1) LV11987B (fr)
MD (1) MD1486G2 (fr)
TJ (1) TJ286B (fr)
WO (1) WO1994009813A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH08305892A (ja) * 1995-05-11 1996-11-22 Sega Enterp Ltd 画像処理装置及びこれを備えたゲーム装置
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP1117425A2 (fr) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Procedes pour traiter les troubles non thyroidiens
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
EP1670413A4 (fr) 2003-08-21 2009-07-08 Tercica Inc Methodes destinees a reduire la graisse viscerale par augmentation des taux du facteur de croissance insulinomimetique de type i (igf-i)
RU2317118C1 (ru) * 2006-09-21 2008-02-20 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения липодистрофии у больных сахарным диабетом
US20250270167A1 (en) * 2021-07-29 2025-08-28 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid and use thereof, recombinant protein containing same and recombinant protein conjugate
US20240317832A1 (en) * 2021-07-29 2024-09-26 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
EP0669832A1 (fr) 1995-09-06
DE69305091T2 (de) 1997-03-13
ES2095086T3 (es) 1997-02-01
AU5451294A (en) 1994-05-24
TJ286B (en) 2000-12-13
MD1486F2 (en) 2000-06-30
GR3022074T3 (en) 1997-03-31
JPH08502969A (ja) 1996-04-02
WO1994009813A1 (fr) 1994-05-11
ATE143267T1 (de) 1996-10-15
AU675996B2 (en) 1997-02-27
MD960245A (en) 1997-12-31
MD1486G2 (ro) 2001-11-30
EP0669832B1 (fr) 1996-09-25
CA2145501C (fr) 2004-08-10
LV11987A (lv) 1998-03-20
LV11987B (en) 1998-06-20
DE69305091D1 (de) 1996-10-31
CA2145501A1 (fr) 1994-05-11

Similar Documents

Publication Publication Date Title
DK0536226T3 (fr)
ATE61523T1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
DK0669832T3 (da) Fremgangsmåde til behandling eller forebyggelse af fedme
KR950701937A (ko) 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives)
HUT64368A (en) Ligand to receptor c-kit and method for its utilization
IL95505A (en) Neuro-peptide containing erection-inducing compositions and use thereof
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DK0639979T3 (da) Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf
KR920700227A (ko) 초고활성 인체 인슐린 동족체
EP1077721B8 (fr) Prevention et traitement de l'hypergastrinemie
KR900003205A (ko) 제약 화합물
DK0654994T3 (da) Anvendelse af cineol eller menthol til behandling af astma
JPS5344616A (en) Injections
GB2304342A (en) Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
EP0317933A3 (fr) Traitement de fibromyalgie
ATE70186T1 (de) Thyrotropin abgebende hormonanaloge fuer verletzungen am zentralnervensystem.
DK0586592T3 (da) Insulin- og amylinholdig sammensætning til behandling af insulindeficiente pattedyr
志田寛 et al. Studies on Experimental Peptic Ulcer
BR9805227A (pt) Composto para tratamento, controle e eliminação de cisticercose em rebanho bovino.
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.
KR920007624A (ko) 단백질 의약품의 경구투여용 조성물
UA39708A (uk) Спосіб лікування хворих з післяампутаційним больовим синдромом
KR910014397A (ko) 장 내피 이온-분비를 억제하는 펩티드 유도체